

Extended Data:

Extended data table 1: Common post-acute sequelae of COVID-19; post-acute sequelae due to COVID-19 with excess burden greater than 10 per 1000 persons at 6-month are presented

Extended data table 2: Common post-acute sequelae of COVID-19 which required hospitalization; post-acute sequelae due to COVID-19 with excess burden greater than 10 per 1000 persons at 6-month are presented

Extended Data figure legends:

Extended data figure 1a: Cohort flow for COVID-19 vs. users of the Veteran Health Administration

Extended data figure 1b: Cohort flow for hospitalized patients with COVID-19 vs. hospitalized patients with seasonal influenza

Extended data figure 2a: Study timeline for COVID-19 vs. users of the Veteran Health Administration

Extended data figure 2b: Study timeline for hospitalized patients with COVID-19 vs. hospitalized patients with seasonal influenza

Extended data Figure 3a: Risk of incident post-acute diagnoses in COVID-19. All users of the Veteran Health Administration healthcare system served as the referent category. Outcomes were ascertained from day 30 after COVID-19 diagnosis until end of follow-up. Adjusted hazard ratios for incident diagnoses that are larger than one and P value less than 6.57×10^{-5} are presented. Diagnoses are grouped based on diagnosis groups and ordered based on hazard ratio from high to low within each diagnosis group. Hazard ratios (dots) and 95% confidence intervals (bars) are presented on log 10 scale.

Extended data Figure 3b: Risk of incident post-acute medication use in COVID-19. All users of the Veteran Health Administration healthcare system served as the referent category. Outcomes were ascertained from day 30 after COVID-19 diagnosis until end of follow-up. Adjusted hazard ratios for incident medications use that are larger than one and P value less than 6.57×10^{-5} are presented. Medications are grouped based on medication groups and ordered based on hazard ratio from high to low within each medication group. Hazard ratios (dots) and 95% confidence intervals (bars) are presented on log 10 scale.

Extended data Figure 3c: Risk of incident post-acute laboratory abnormalities in COVID-19. All users of the Veteran Health Administration healthcare system served as the referent category. Outcomes were ascertained from day 30 after COVID-19 diagnosis until end of follow-up. Adjusted hazard ratios for incident laboratory abnormalities that are larger than one and P value less than 6.57×10^{-5} are presented. Laboratory abnormalities are grouped based on higher or lower than the normal range and ordered based on hazard ratio from high to low within each group. Hazard ratios (dots) and 95% confidence intervals (bars) are presented on log 10 scale.

Extended data Figure 4a: Risk of incident post-acute diagnoses in COVID-19 patients who had been hospitalized for COVID-19. People who had been hospitalized with seasonal influenza served as the referent category. Outcomes were ascertained from day 30 after hospital admission until end of follow-up. Adjusted hazard ratios for incident diagnoses that are larger than one and P value less than 6.57×10^{-5} are presented. Diagnoses are grouped based on diagnosis groups and ordered based on hazard ratio from high to low within each diagnosis group. Hazard ratios (dots) and 95% confidence intervals (bars) are presented on log 10 scale.

Extended data Figure 4b: Risk of incident post-acute medication use in patients with COVID-19 who had been hospitalized for COVID-19. People who had been hospitalized with seasonal influenza served as the referent category. Outcomes were ascertained from day 30

after hospital admission until end of follow-up. Adjusted hazard ratios for incident medication use that are larger than one and P value less than 6.57×10^{-5} are presented. Medication use are grouped based on medication groups and ordered based on hazard ratio from high to low within each medication group. Hazard ratios (dots) and 95% confidence intervals (bars) are presented on log 10 scale.

Extended data Figure 4c: Risk of incident post-acute laboratory abnormalities in patients with COVID-19 who had been hospitalized for COVID-19. People who had been hospitalized with seasonal influenza served as the referent category. Outcomes were ascertained from day 30 after hospital admission until end of follow-up. Adjusted hazard ratios for incident laboratory abnormalities that are larger than one and P value less than 6.57×10^{-5} are presented. Laboratory abnormalities are grouped based on higher or lower than the normal range and ordered based on hazard ratio from high to low within each group. Hazard ratios (dots) and 95% confidence intervals (bars) are presented on log 10 scale.

Extended data figure 5: Flowchart of the overall analytic approach

Extended data table 1: Common post-acute sequelae of COVID-19; post-acute sequelae due to COVID-19 with excess burden greater than 10 per 1000 persons at 6-month are presented

Grouping	Outcomes	P value	Hazard Ratio (95% Confidence interval)	Excess burden per 1000 COVID-19 patients at 6-months (95% Confidence interval)
Diagnoses				
SYM	Respiratory signs and symptoms	9.10×10 ⁻¹³¹	2.25 (2.11, 2.41)	46.18 (43.63, 48.57)
SYM	Nervous system signs and symptoms	3.62×10 ⁻⁷³	1.86 (1.74, 1.99)	31.39 (28.82, 33.81)
SYM	Malaise and fatigue	1.80×10 ⁻⁹⁶	2.42 (2.23, 2.63)	27.22 (25.54, 28.77)
CIR	Hypertension	1.60×10 ⁻²³	1.45 (1.34, 1.55)	26.50 (21.99, 30.72)
RSP	Respiratory failure; insufficiency; arrest	3.00×10 ⁻¹³⁴	5.15 (4.52, 5.87)	24.73 (23.89, 25.47)
END	Disorders of lipid metabolism	1.42×10 ⁻¹⁷	1.31 (1.23, 1.39)	23.96 (18.96, 28.69)
NVS	Sleep wake disorders	3.42×10 ⁻²⁷	1.43 (1.34, 1.53)	22.66 (19.09, 26.01)
END	Fluid and electrolyte disorders	2.20×10 ⁻⁶²	2.10 (1.92, 2.29)	19.74 (18.08, 21.25)
INF	Bacterial infections	1.12×10 ⁻⁷⁸	2.81 (2.52, 3.12)	18.87 (17.67, 19.95)
MUS	Muscle disorders	7.77×10 ⁻⁶⁹	2.47 (2.23, 2.73)	18.55 (17.19, 19.77)
BLD	Anemia	1.07×10 ⁻⁵⁶	2.08 (1.90, 2.28)	18.55 (16.91, 20.05)
CIR	Cardiac dysrhythmias	1.50×10 ⁻⁵⁷	2.26 (2.04, 2.50)	17.53 (16.05, 18.86)
DIG	Esophageal disorders	7.28×10 ⁻²⁴	1.44 (1.34, 1.55)	16.69 (13.88, 19.32)
MBD	Trauma- and stressor-related disorders	3.35×10 ⁻²⁴	1.50 (1.39, 1.62)	16.45 (13.75, 18.95)
MUS	Musculoskeletal pain, not low back pain	1.82×10 ⁻⁰⁹	1.19 (1.12, 1.25)	15.70 (10.85, 20.32)
GEN	Acute renal failure	3.42×10 ⁻⁶²	2.61 (2.33, 2.93)	15.55 (14.39, 16.59)
SYM	Circulatory signs and symptoms	6.31×10 ⁻³⁸	1.77 (1.62, 1.93)	15.23 (13.43, 16.90)
CIR	Chest pain	2.23×10 ⁻³⁷	1.80 (1.64, 1.97)	14.94 (13.16, 16.56)
NVS	Other specified nervous system disorders	1.17×10 ⁻⁴⁰	1.99 (1.80, 2.21)	14.08 (12.56, 15.45)
DIG	Gastrointestinal disorders	1.45×10 ⁻³³	1.73 (1.58, 1.89)	14.07 (12.26, 15.72)
END	Diabetes mellitus	1.91×10 ⁻²³	1.60 (1.46, 1.75)	14.00 (11.73, 16.07)
END	Obesity	2.43×10 ⁻²⁰	1.48 (1.36, 1.61)	13.04 (10.67, 15.22)
SYM	Dysphagia	7.71×10 ⁻⁴⁷	2.32 (2.07, 2.60)	12.77 (11.59, 13.83)
GEN	Urinary tract infections	2.68×10 ⁻⁴²	2.19 (1.96, 2.46)	12.54 (11.27, 13.67)
MBD	Depressive disorders	6.57×10 ⁻¹⁴	1.33 (1.24, 1.43)	12.40 (9.48, 15.12)
SYM	Abdominal pain and other digestive/abdomen signs and symptoms	1.03×10 ⁻¹⁷	1.39 (1.29, 1.49)	12.22 (9.75, 14.51)
NVS	Neurocognitive disorders	1.23×10 ⁻⁴³	2.51 (2.21, 2.86)	11.87 (10.77, 12.84)

RSP	Lower respiratory disease	6.11×10^{-53}	3.03 (2.63, 3.49)	11.68 (10.80, 12.44)
INF	Septicemia	2.79×10^{-56}	3.63 (3.09, 4.26)	11.48 (10.72, 12.13)
CIR	Coronary atherosclerosis and other heart disease	3.94×10^{-24}	1.67 (1.51, 1.84)	11.37 (9.59, 12.99)
CIR	Heart failure	3.47×10^{-36}	2.13 (1.89, 2.39)	11.22 (9.97, 12.34)
MBD	Anxiety and fear-related disorders	3.85×10^{-15}	1.38 (1.27, 1.49)	10.69 (8.33, 12.88)
SYM	Genitourinary signs and symptoms	2.81×10^{-20}	1.55 (1.41, 1.70)	10.03 (8.25, 11.67)
Medication use				
CN	Non-opioid analgesics	3.26×10^{-97}	2.02 (1.89, 2.15)	45.07 (41.99, 47.96)
BL	Anticoagulants	1.20×10^{-169}	2.98 (2.76, 3.22)	44.31 (42.48, 46.01)
RE	Bronchodilators, sympathomimetic, inhalation	1.70×10^{-128}	2.84 (2.61, 3.09)	36.26 (34.48, 37.89)
GA	Hyperosmotic laxatives	5.75×10^{-65}	1.78 (1.67, 1.91)	28.87 (26.30, 31.29)
GA	Gastric medications	8.71×10^{-49}	1.74 (1.61, 1.87)	26.70 (23.90, 29.32)
RE	Non-opioid-containing antitussives/expectorants	6.84×10^{-84}	2.76 (2.49, 3.06)	22.71 (21.30, 23.98)
GA	Stimulant laxatives	1.62×10^{-57}	1.89 (1.74, 2.04)	22.27 (20.22, 24.18)
CV	Beta blockers/related	1.97×10^{-50}	2.08 (1.89, 2.29)	20.42 (18.49, 22.17)
CV	Antilipemic agents	2.35×10^{-21}	1.52 (1.40, 1.66)	19.14 (15.79, 22.23)
CN	Opioid analgesics	8.28×10^{-32}	1.53 (1.43, 1.64)	19.01 (16.35, 21.49)
CN	Antidepressants	3.27×10^{-24}	1.51 (1.39, 1.63)	18.36 (15.35, 21.16)
RE	Antiasthma	1.40×10^{-57}	2.43 (2.18, 2.70)	17.08 (15.69, 18.32)
CV	Calcium channel blockers	6.45×10^{-40}	1.99 (1.79, 2.20)	16.69 (14.86, 18.34)
HS	Insulin	1.02×10^{-58}	2.66 (2.36, 2.99)	16.19 (14.95, 17.29)
VT	Vitamin D	1.21×10^{-22}	1.45 (1.35, 1.57)	16.10 (13.32, 18.69)
TN	Potassium	4.57×10^{-47}	2.02 (1.84, 2.23)	15.95 (14.37, 17.39)
HS	Glucocorticoids	4.66×10^{-26}	1.51 (1.40, 1.63)	14.87 (12.54, 17.03)
CV	Alpha blockers/related	4.29×10^{-27}	1.65 (1.50, 1.80)	14.55 (12.40, 16.52)
GA	Stool softener	6.44×10^{-41}	1.95 (1.77, 2.14)	14.39 (12.83, 15.82)
VT	Vitamin C	1.34×10^{-64}	3.44 (2.98, 3.97)	13.67 (12.81, 14.42)
CV	Loop diuretics	9.84×10^{-44}	2.21 (1.98, 2.48)	13.57 (12.24, 14.77)
DE	Antifungal, topical	6.79×10^{-24}	1.57 (1.43, 1.71)	12.44 (10.43, 14.29)
DE	Anti-inflammatory, topical	9.88×10^{-11}	1.23 (1.16, 1.31)	12.35 (8.86, 15.63)
MS	Nonsalicylate NSAIDs, antirheumatic	2.13×10^{-09}	1.24 (1.15, 1.33)	11.45 (7.95, 14.72)
CN	Anticonvulsants	1.47×10^{-14}	1.39 (1.28, 1.51)	11.01 (8.53, 13.30)
AH	Antihistamines	2.34×10^{-17}	1.46 (1.34, 1.59)	10.99 (8.79, 13.00)
CN	Benzodiazepine derivative sedatives/hypnotics	1.46×10^{-28}	1.82 (1.64, 2.03)	10.76 (9.29, 12.08)

TN	Magnesium	1.04×10^{-32}	2.00 (1.79, 2.25)	10.76 (9.45, 11.92)
Laboratory abnormalities				
Low	Hematocrit	6.28×10^{-98}	1.85 (1.75, 1.96)	53.25 (49.45, 56.86)
Low	Hemoglobin	3.40×10^{-100}	1.92 (1.80, 2.03)	51.35 (47.80, 54.72)
Low	Serum albumin	2.55×10^{-75}	2.12 (1.95, 2.29)	24.63 (22.77, 26.35)
High	Serum chloride	1.11×10^{-31}	1.53 (1.42, 1.64)	18.39 (15.81, 20.80)
Low	Serum potassium	3.43×10^{-38}	1.77 (1.62, 1.93)	15.41 (13.59, 17.09)
Low	Serum calcium	1.25×10^{-39}	1.80 (1.65, 1.97)	15.37 (13.61, 17.00)
High	Total white blood cell count	6.68×10^{-29}	1.57 (1.45, 1.70)	14.66 (12.52, 16.64)
Low	Total white blood cell count	1.23×10^{-23}	1.49 (1.38, 1.61)	14.25 (11.87, 16.45)
High	Alanine aminotransferase	3.22×10^{-19}	1.38 (1.28, 1.48)	13.99 (11.28, 16.52)
Low	Carbon dioxide	2.57×10^{-27}	1.56 (1.44, 1.69)	13.88 (11.79, 15.82)
High	Blood urea nitrogen	4.40×10^{-25}	1.56 (1.44, 1.70)	13.24 (11.15, 15.16)
Low	Serum sodium	3.71×10^{-17}	1.35 (1.26, 1.44)	13.04 (10.33, 15.58)
Low	Serum total protein	2.75×10^{-38}	2.20 (1.95, 2.47)	10.97 (9.80, 12.00)
High	International Normalized Ratio	1.53×10^{-37}	2.20 (1.95, 2.48)	10.96 (9.78, 12.00)
High	Triglycerides	3.01×10^{-07}	1.17 (1.10, 1.24)	10.51 (6.67, 14.14)
High	Prothrombin time	1.41×10^{-35}	2.15 (1.91, 2.43)	10.51 (9.33, 11.55)
<p>Diagnosis group: BLD=Diseases of the Blood and Blood Forming Organs and Certain Disorders Involving the Immune Mechanism; CIR=Diseases of the Circulatory System; DIG=Diseases of the Digestive System; END=Endocrine, Nutritional and Metabolic Diseases; GEN=Diseases of the Genitourinary System; INF=Certain Infectious and Parasitic Diseases; MBD=Mental, Behavioral and Neurodevelopmental Disorders; MUS=Diseases of the Musculoskeletal System and Connective Tissue; NVS=Diseases of the Nervous System; RSP=Diseases of the Respiratory System; SYM=Symptoms, Signs and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified.</p> <p>Medication group: AH=Antihistamines; BL=Blood Products/Modifiers/Volume Expanders; CN=Central Nervous System Medications; CV=Cardiovascular Medications; DE=Dermatological Agents; GA=Gastrointestinal Medications; HS=Hormones/Synthetics/Modifiers; MS=Musculoskeletal Medications; RE=Respiratory Tract Medications; TN=Therapeutic Nutrients/Minerals/Electrolytes; VT=Vitamins.</p> <p>Hazard ratio, burden and P value of common post-acute sequelae of COVID-19 in people with COVID-19 compared to users of the Veterans Health Administration (VHA). All users of the VHA served as the referent category. Results based on survival models adjusted through overlap weighting. Outcomes were ascertained from day 30 after COVID-19 diagnosis until end of follow-up. Outcomes selected based on hazard ratio larger than one, P value less than 6.57×10^{-5} and excess burden larger than 10 per 1000 COVID-19 patients at 6-months. Within each domain, outcomes are ranked based on excess burden from high to low.</p>				

Extended data table 2: Common post-acute sequelae of COVID-19 which required hospitalization; post-acute sequelae due to COVID-19 with excess burden greater than 10 per 1000 persons at 6-month are presented

Grouping	Outcomes	P value	Hazard Ratio (95% Confidence interval)	Excess burden per 1000 hospitalized COVID-19 patients at 180 days (95% Confidence interval)
Diagnoses				
RSP	Respiratory failure; insufficiency; arrest	3.67×10^{-65}	2.39 (2.16, 2.65)	74.79 (68.91, 80.15)
END	Fluid and electrolyte disorders	2.00×10^{-21}	1.58 (1.44, 1.74)	52.52 (43.35, 60.94)
SYM	Malaise and fatigue	4.12×10^{-17}	1.54 (1.39, 1.70)	44.30 (35.44, 52.39)
END	Disorders of lipid metabolism	1.09×10^{-06}	1.32 (1.18, 1.47)	43.17 (26.97, 57.93)
GEN	Acute renal failure	7.27×10^{-16}	1.56 (1.40, 1.74)	36.59 (29.01, 43.45)
SYM	Nervous system signs and symptoms	9.76×10^{-08}	1.30 (1.18, 1.43)	35.09 (23.09, 46.14)
INF	Bacterial infections	6.83×10^{-12}	1.43 (1.29, 1.59)	33.73 (25.19, 41.52)
MUS	Muscle disorders	5.68×10^{-10}	1.42 (1.27, 1.59)	28.81 (20.68, 36.15)
BLD	Anemia	4.32×10^{-08}	1.36 (1.22, 1.51)	28.09 (18.91, 36.41)
INF	Septicemia	8.99×10^{-16}	1.74 (1.52, 2.00)	27.82 (22.33, 32.64)
GEN	Urinary tract infections	1.05×10^{-13}	1.65 (1.44, 1.88)	26.97 (21.04, 32.20)
NVS	Other specified nervous system disorders	7.20×10^{-10}	1.49 (1.31, 1.69)	25.77 (18.59, 32.14)
END	Malnutrition	9.07×10^{-17}	1.93 (1.65, 2.25)	24.65 (20.16, 28.52)
SYM	Dysphagia	1.68×10^{-09}	1.45 (1.28, 1.63)	23.65 (16.83, 29.73)
NVS	Neurocognitive disorders	2.11×10^{-09}	1.58 (1.36, 1.83)	22.83 (16.42, 28.39)
END	Nutritional and metabolic disorders	3.65×10^{-09}	1.48 (1.30, 1.69)	22.68 (16.05, 28.53)
SYM	Shock	4.43×10^{-23}	3.06 (2.45, 3.82)	21.59 (18.97, 23.70)
SKN	Pressure ulcer of skin	8.70×10^{-12}	1.73 (1.48, 2.03)	20.45 (15.64, 24.57)
CIR	Hypotension	1.49×10^{-07}	1.43 (1.25, 1.64)	19.09 (12.71, 24.70)
DIG	Gastrointestinal disorders	2.88×10^{-05}	1.29 (1.14, 1.45)	18.31 (10.26, 25.52)
SYM	Circulatory signs and symptoms	3.50×10^{-05}	1.29 (1.15, 1.46)	17.80 (9.90, 24.85)
RSP	Lower respiratory disease	4.57×10^{-07}	1.44 (1.25, 1.67)	16.79 (10.96, 21.88)
MBD	Anxiety and fear-related disorders	1.83×10^{-05}	1.37 (1.19, 1.59)	15.72 (9.11, 21.48)
CIR	Acute pulmonary embolism	1.15×10^{-14}	2.57 (2.02, 3.26)	15.33 (12.67, 17.43)
BLD	Coagulation and hemorrhagic disorders	1.36×10^{-07}	1.58 (1.33, 1.87)	14.25 (9.67, 18.13)
RSP	Postprocedural or postoperative respiratory system complication	1.21×10^{-19}	5.07 (3.57, 7.21)	12.02 (10.77, 12.90)
CIR	Acute phlebitis; thrombophlebitis and thromboembolism	2.57×10^{-07}	1.71 (1.39, 2.09)	11.88 (8.08, 15.00)


Medication use				
BL	Anticoagulants	3.43×10 ⁻²⁵	1.55 (1.43, 1.68)	81.04 (67.76, 93.46)
CN	Non-opioid analgesics	3.37×10 ⁻⁰⁸	1.31 (1.19, 1.44)	55.26 (36.87, 72.35)
GA	Hyperosmotic laxatives	7.33×10 ⁻¹⁵	1.43 (1.31, 1.57)	50.65 (39.29, 61.16)
GA	Stimulant laxatives	2.70×10 ⁻¹⁶	1.50 (1.36, 1.65)	47.02 (37.22, 56.01)
DE	Local anesthetics, topical	4.47×10 ⁻¹¹	1.51 (1.33, 1.70)	29.44 (21.81, 36.25)
VT	Vitamin C	2.84×10 ⁻³⁰	3.04 (2.51, 3.68)	28.78 (25.78, 31.27)
IM	Vaccines	8.32×10 ⁻²¹	2.04 (1.76, 2.37)	27.67 (23.33, 31.42)
HS	Insulin	2.05×10 ⁻⁰⁸	1.44 (1.27, 1.64)	26.10 (17.96, 33.33)
TN	Potassium	3.07×10 ⁻⁰⁶	1.29 (1.16, 1.44)	23.95 (14.56, 32.47)
TN	Zinc	4.18×10 ⁻³⁵	8.52 (6.07, 11.96)	22.78 (21.54, 23.66)
CN	Benzodiazepine derivative sedatives/hypnotics	9.54×10 ⁻⁰⁹	1.48 (1.29, 1.69)	21.57 (15.08, 27.29)
DE	Antifungal, topical	3.78×10 ⁻⁰⁶	1.34 (1.18, 1.52)	19.97 (12.16, 26.93)
CN	Antipsychotics	1.41×10 ⁻⁰⁸	1.57 (1.34, 1.83)	18.59 (13.04, 23.36)
DE	Dermatologicals, topical	9.50×10 ⁻⁰⁷	1.44 (1.24, 1.66)	16.82 (10.78, 22.07)
RS	Laxatives, rectal	2.63×10 ⁻⁰⁵	1.39 (1.19, 1.61)	12.88 (7.37, 17.64)
OR	Mouthwashes	4.10×10 ⁻⁰⁷	1.57 (1.32, 1.87)	12.71 (8.44, 16.31)
VT	Thiamine	3.92×10 ⁻⁰⁵	1.53 (1.25, 1.88)	10.15 (5.84, 13.69)
Laboratory abnormalities				
Low	Hemoglobin	2.80×10 ⁻⁰⁶	1.28 (1.16, 1.42)	48.56 (29.34, 66.28)
Low	Hematocrit	1.14×10 ⁻⁰⁵	1.26 (1.13, 1.39)	48.04 (27.56, 67.01)
Low	Serum albumin	1.18×10 ⁻¹²	1.42 (1.29, 1.56)	45.03 (33.92, 55.24)
Low	Serum total protein	2.02×10 ⁻¹⁹	1.81 (1.59, 2.06)	33.39 (27.63, 38.49)
High	Alanine aminotransferase	2.18×10 ⁻⁰⁸	1.42 (1.25, 1.60)	25.70 (17.62, 32.91)
High	Platelet count	2.22×10 ⁻¹⁶	1.94 (1.65, 2.26)	24.31 (19.85, 28.15)
Low	Serum calcium	3.03×10 ⁻⁰⁵	1.26 (1.13, 1.41)	22.33 (12.41, 31.31)
Low	Serum potassium	5.16×10 ⁻⁰⁶	1.31 (1.17, 1.47)	21.79 (13.08, 29.62)
High	High-sensitivity C-reactive protein	9.99×10 ⁻¹⁶	2.15 (1.78, 2.59)	20.60 (16.89, 23.69)
High	Ferritin	2.04×10 ⁻⁰⁹	1.72 (1.44, 2.05)	16.76 (12.21, 20.58)
High	Total cholesterol	4.97×10 ⁻⁰⁵	1.40 (1.19, 1.65)	13.25 (7.38, 18.27)
High	Serum phosphate	1.17×10 ⁻⁰⁵	1.47 (1.24, 1.74)	12.22 (7.31, 16.38)
High	Serum sodium	3.99×10 ⁻⁰⁶	1.49 (1.26, 1.77)	11.83 (7.35, 15.62)
High	C-reactive protein	7.76×10 ⁻⁰⁷	1.67 (1.37, 2.05)	10.78 (7.14, 13.76)
Diagnosis group: BLD=Diseases of the Blood and Blood Forming Organs and Certain Disorders Involving the Immune Mechanism; CIR=Diseases of the Circulatory System; DIG=Diseases of the Digestive System; END=Endocrine, Nutritional and Metabolic Diseases; GEN=Diseases of the				

Genitourinary System; INF=Certain Infectious and Parasitic Diseases; MBD=Mental, Behavioral and Neurodevelopmental Disorders; MUS=Diseases of the Musculoskeletal System and Connective Tissue; NVS=Diseases of the Nervous System; RSP=Diseases of the Respiratory System; SKN=Diseases of the Skin and Subcutaneous Tissue; SYM=Symptoms, Signs and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified.


Medication group: BL=Blood Products/Modifiers/Volume Expanders; CN=Central Nervous System Medications; DE=Dermatological Agents; GA=Gastrointestinal Medications; HS=Hormones/Synthetics/Modifiers; IM=Immunological Agents; OR=Dental and Oral Agents, Topical; RS=Rectal, Local; TN=Therapeutic Nutrients/Minerals/Electrolytes; VT=Vitamins.

Hazard ratio, burden and P value of common post-acute sequelae of COVID-19 which require hospitalization in people who had been hospitalized with COVID-19 compared to people who had been hospitalized with seasonal influenza. People who had been hospitalized with seasonal influenza served as the referent category. Results based on survival models adjusted through overlap weighting. Outcomes were ascertained from day 30 after hospital admission until end of follow-up. Outcomes selected based on hazard ratio larger than one, P value less than 6.57×10^{-5} and excess burden larger than 10 per 1000 COVID-19 patients at 6-months. Within each domain, outcomes are ranked based on excess burden from high to low.


Extended data figure 1a: Cohort flow for COVID-19 vs. users of the Veteran Health Administration




Extended data figure 1b: Cohort flow for hospitalized patients with COVID-19 vs. hospitalized patients with seasonal influenza




Extended data figure 2a: Study timeline for COVID-19 vs. users of the Veteran Health Administration




Extended data figure 2b: Study timeline for hospitalized patients with COVID-19 vs. hospitalized patients with seasonal influenza




Extended data figure 3A. Diagnoses in COVID-19 vs. VHA users




Extended data figure 3B. Medication use in COVID-19 vs VHA users




Extended data figure 3C. Laboratory abnormalities in COVID-19 vs. VHA users




Extended data figure 4A. Diagnoses in hospitalized COVID-19 vs. influenza



Extended data figure 4B. Medication use in hospitalized COVID-19 vs. influenza



Extended figure 4C. Laboratory abnormalities in hospitalized COVID-19 vs. influenza



Extended data figure 5: Flowchart of the overall analytic approach

